The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.
Amita Patnaik
Research Funding - Lilly
Lee S. Rosen
Research Funding - Lilly
Sara M. Tolaney
No relevant relationships to disclose
Anthony W. Tolcher
Consultant or Advisory Role - A.P. Pharma (U); Abbott Laboratories (U); AbGenomics International (U); Abraxis BioScience (U); Actavis (U); Adnexus (U); Ambit BioSciences (U); Amgen (U); Aragon Pharmaceuticals (U); ARIAD (U); Arresto (U); Astellas Pharma (U); Astex Therapeutics (U); Bayer (U); BIND Biosciences (U); Bristol-Myers Squibb Japan (U); Celator Pharmaceuticals (U); Celgene (U); Clovis (U); Complete Genomics (U); Cougar Biotechnology (U); Curis (U); CytomX Therapeutics (U); Daiichi Sankyo (U); De Novo Pharmaceuticals (U); Dendreon (U); Dicerna (U); Eisai (U); EMD Serono (U); Endo Pharmaceuticals (U); Enzon (U); Everist Genomics (U); Exelixis (U); Five Prime Therapeutics (U); Galapagos NV (U); Genentech (U); Geron (U); GlaxoSmithKline (U); HUYA Bioscience International (U); Icon Clinical Research (U); Inovio Pharmaceuticals (U); Insert Therapeutics (U); Intellikine (U); Invivis (U); Janssen (U); Johnson & Johnson (U); Lilly (U); Merck (U); MethylGene (U); Micromet (U); NantWorks (U); Nektar (U); Neumedicines (U); Novartis (U); Oncogenex (U); OncoMed (U); Onyx (U); Otsuka (U); Pfizer (U); Pharmacyclics (U); PPD Inc. (U); Precision Health Holdings (U); ProNAi (U); Regeneron (U); Sanofi (U); Spectrum Pharmaceuticals (U); Sunovion (U); Symphogen (U); Triphase Accelerator Corp (U); Vaccinex (U); Veeda Oncology (U); Zyngenia (U)
Jonathan Wade Goldman
Research Funding - Lilly
Leena Gandhi
No relevant relationships to disclose
Kyriakos P. Papadopoulos
Research Funding - Lilly
Muralidhar Beeram
Research Funding - Lilly
Drew Warren Rasco
Research Funding - Lilly
Scott P. Myrand
Employment or Leadership Position - Eli Lilly and Company
Stock Ownership - Eii Lilly and Company
Palaniappan Kulanthaivel
Employment or Leadership Position - Lilly
Consultant or Advisory Role - Eli Lilly and Company
Stock Ownership - Lilly
Joan M. Andrews
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Martin Frenzel
Employment or Leadership Position - Lilly
Damien Cronier
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Edward M. Chan
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Keith Flaherty
Consultant or Advisory Role - Lilly
Patrick Y. Wen
Consultant or Advisory Role - Merck; Novartis
Honoraria - Merck
Research Funding - ARIAD; AstraZeneca; Celldex; Exelixis; Merck; Momenta Pharmaceuticals; NPM Pharma; Roche/Genentech; Sanofi ; Vascular Biogenics
Geoffrey Shapiro
Honoraria - Lilly
Research Funding - Lilly